四川汇宇海玥医药科技

Sichuan Huiyu Haiyue Pharmaceutical Technology is the innovative drug research and development subsidiary of Huiyu Pharmaceutical (688553.SH). Based in Chengdu, China, the company focuses on the discovery and development of small molecule and biologic therapeutics primarily for oncology and immunology. Its pipeline includes several clinical-stage programs, such as a KRAS G12C inhibitor, a TYK2 inhibitor, and a PD-L1/TGF-beta bifunctional fusion protein. The company leverages its parent's manufacturing and commercialization infrastructure to advance its portfolio of First-in-class and Best-in-class candidates. Huiyu Haiyue represents the core of the group's strategic shift toward innovative medicine and operates state-of-the-art R&D facilities in the Chengdu Tianfu International Bio-Town.